Grace Therapeutics, Inc. (GRCE) stock
GRCENasdaqPharmaceutical PreparationsFiscal year ends March 31
$1.81−0.04 (-2.43%)
Close on Nov 12, 2026Market cap $38.08MP/E –Yield –
Grace Therapeutics total assets
Total assets on the balance sheet at the end of each period.
Grace Therapeutics's total assets was $57.70M at Sep 30, 2026. For fiscal 2026 it was $66.65M, down 7.4% from the year before. The highest annual figure on record is $128.62M in fiscal 2022.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Mar 31, 2026 | $66.65M | -7.4% |
| FY2025 | Mar 31, 2025 | $71.99M | -1.8% |
| FY2024 | Mar 31, 2024 | $73.30M | -7.4% |
| FY2023 | Mar 31, 2023 | $79.12M | -38.5% |
| FY2022 | Mar 31, 2022 | $128.62M | +105.9% |
| FY2021 | Mar 31, 2021 | $62.46M | +173.3% |
| FY2020 | Mar 31, 2020 | $22.85M | -38.1% |
| FY2019 | Mar 31, 2019 | $36.90M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2027CQ3 2026 | Sep 30, 2026 | $57.70M | -13.3% |
| Q1 FY2027CQ2 2026 | Jun 30, 2026 | $50.07M | -28.3% |
| Q4 FY2026CQ1 2026 | Mar 31, 2026 | $66.65M | -7.4% |
| Q3 FY2026CQ4 2025 | Dec 31, 2025 | $68.49M | +11.9% |
| Q2 FY2026CQ3 2025 | Sep 30, 2025 | $66.58M | +1.9% |
| Q1 FY2026CQ2 2025 | Jun 30, 2025 | $69.81M | +0.1% |
| Q4 FY2025CQ1 2025 | Mar 31, 2025 | $71.99M | -1.8% |
| Q3 FY2025CQ4 2024 | Dec 31, 2024 | $61.22M | -19.6% |
| Q2 FY2025CQ3 2024 | Sep 30, 2024 | $65.35M | -16.4% |
| Q1 FY2025CQ2 2024 | Jun 30, 2024 | $69.72M | -4.5% |
| Q4 FY2024CQ1 2024 | Mar 31, 2024 | $73.30M | -7.4% |
| Q3 FY2024CQ4 2023 | Dec 31, 2023 | $76.19M | -34.8% |
| Q2 FY2024CQ3 2023 | Sep 30, 2023 | $78.21M | -35.3% |
| Q1 FY2024CQ2 2023 | Jun 30, 2023 | $73.03M | -41.5% |
| Q4 FY2023CQ1 2023 | Mar 31, 2023 | $79.12M | -38.5% |
| Q3 FY2023CQ4 2022 | Dec 31, 2022 | $116.80M | +2.3% |
| Q2 FY2023CQ3 2022 | Sep 30, 2022 | $120.91M | +0.9% |
| Q1 FY2023CQ2 2022 | Jun 30, 2022 | $124.93M | +106.7% |
| Q4 FY2022CQ1 2022 | Mar 31, 2022 | $128.62M | +105.9% |
| Q3 FY2022CQ4 2021 | Dec 31, 2021 | $114.23M | +276.9% |
| Q2 FY2022CQ3 2021 | Sep 30, 2021 | $119.80M | +766.1% |
| Q1 FY2022CQ2 2021 | Jun 30, 2021 | $60.45M | +200.1% |
| Q4 FY2021CQ1 2021 | Mar 31, 2021 | $62.46M | +173.3% |
| Q3 FY2021CQ4 2020 | Dec 31, 2020 | $30.30M | -17.9% |
| Q2 FY2021CQ3 2020 | Sep 30, 2020 | $13.83M | – |
| Q1 FY2021CQ2 2020 | Jun 30, 2020 | $20.14M | – |
| Q4 FY2020CQ1 2020 | Mar 31, 2020 | $22.85M | – |
| Q4 FY2019CQ1 2019 | Mar 31, 2019 | $36.90M | – |
See a number that looks wrong?